A Phase 1/2 interventional study of AZD4512 monotherapy in B-cell Acute Lymphoblastic Leukemia (B-ALL), sponsored by AstraZeneca. Recruiting at 27 sites in 9 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by AstraZeneca · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 725 studies in Burkitt Lymphoma with a site in United States — 71 open to participants now, 118 under way, 10 of them phase 3. Burkitt Lymphoma · United States.
Among the 725 studies in Burkitt Lymphoma with a site in United States, this one is the 119th largest by planned enrollment of the 594 interventional ones that give a count, is one of 17 that started in 2025, is one of 83 in phase 1/2, reaches primary completion later than 84 of the 117 other live ones, and was the 706th registered.
977 studies on the registry are indexed under Burkitt Lymphoma; 160 are open to participants now.
Browse Burkitt Lymphoma studies →71 of the 725 studies in Burkitt Lymphoma with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18+
Sunil G. Iyer · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18+
AIDS Malignancy Consortium · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 132 Burkitt Lymphoma studies recruiting now, 42 (32%) set no upper age limit and 77 (58%) stop at 75 or younger; 75 take children under 18; 2 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
725 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 341 · Phase 2 323 · Phase 3 51 · Phase 4 1
First in 1988; this study’s year is marked. 17 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 83 is above the median of 36 across 766 interventional studies indexed under Burkitt Lymphoma.
Median enrollment 37 across the 594 interventional studies, 94 across the 40 observational. Of the 560 that completed or were terminated, 172 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
74 of 725 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
AstraZeneca has 4 studies filed under Burkitt Lymphoma — fewer than ten, so there is no comparison to draw.
38 of the studies in Burkitt Lymphoma with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03914625Phase 3National Cancer Institute (NCI)A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia | 2027-09-30 |
| NCT03150693Phase 3Alliance for Clinical Trials in OncologyInotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia | 2027-11-01 |
| NCT04690595PeproMene Bio, Inc.BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL | 2026-11-18 |
| NCT02393157New York Medical CollegeObinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL | 2026-12 |
| NCT06131801Children's Hospital Medical Center, CincinnatiPharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution | 2026-12-01 |
Add all 38 to your calendar (.ics) → With an account.
Among the 725 studies in Burkitt Lymphoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study is intended to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AZD4512 in patients with relapsed/refractory B-Cell acute lymphoblastic leukemia (r/r B-ALL).
In this Phase I/II, open-label multi-center study AZD4512 will be administered to adult/young adult patients (Module 1: >=16 years; Module 2: >=12 years) with relapsed/refractory B-Cell acute lymphoblastic leukemia (B-ALL). This study will have 2 parts: Module 1 - Dose Escalation and Module 2 - Dose Optimization.
The criteria were revised on the registry on Oct 15, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1. Age:
12 years old in Module 2
2. Diagnosis: Known Diagnosis of CD22-positive B-ALL based on criteria established by WHO (Alaggio et al. 2022).
Backfill of Module 1 and Module 2 (DO): R/R B-ALL [Ph(-)] with demonstration of CD22 expression by local assessment in screening.
3. Performance status ( ≤ 2; ≥ 50; LPS ≥ 50)
4. Peripheral lymphoblast count \< 10,000/µL (may receive cytoreduction prior to C1D1 per protocol-specified criteria)
5. Prior therapies:
Participants who have received prior CD22 targeted therapies and were not refractory to these therapies are eligible
6. Prior DLI >4 weeks, prior cell therapy or >8 weeks, alloHSCT >12 weeks
Exclusion Criteria:
Prior/concomitant therapy
If the investigational product is an agent to treat B-ALL and meets the modality criteria, then a specific must be adhered to instead.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Module 1 will evaluate escalating doses of AZD4512 as monotherapy to determine the maximum tolerated dose (MTD) and/or doses of AZD4512 for subsequent evaluation in Module 2 (dose optimization), in participants with relapsed/refractory (R/R) Philadelphia chromosome positive (Ph\[+\]) and negative (Ph\[-\]) B-ALL, R/R as defined by National Comprehensive Cancer Network (NCCN) guidelines.
Combination Product: AZD4512 monotherapy
Module 2 will randomize participants with R/R (as defined by NCCN guidelines) Ph(-) BALL only across 2 to 3 dose levels identified in Module 1 to receive AZD4512 monotherapy for further exploration of the doses. The aim of Module 2 is to identify the recommended Phase 2 dose (RP2D) of AZD4512 monotherapy, evaluate the efficacy and further define the safety profile of AZD4512.
Combination Product: AZD4512 monotherapy
Patients will receive AZD4512 as monotherapy via intravenous infusion. AZD4512 is an antibody-drug conjugate targeting CD22
Module 1 (Dose Escalation): Number of participants with dose-limiting toxicities (DLTs).
DLTs are dose-limiting toxicities as defined in the study protocol.
Time frame: From first dose up to 21 days (DLT period).
Module 1 (Dose Escalation): Frequency, duration and severity of treatment-emergent adverse events (TEAEs), treatment-related adverse events (TRAEs), and serious adverse events (SAEs)
Assessed by the CTCAE criteria version 5.0
Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
Module 1 (Dose Escalation): Frequency of dose interruptions, modifications, delays, and discontinuations due to AEs
Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
Module 1 (Dose Escalation): Number of participants with clinically significant changes in laboratory values, ECGs, performance status, and vital signs
Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
Module 2 (Dose Optimization): Overall response rate (ORR) in participants with R/R Ph(-) B-ALL
To evaluate the efficacy based on NCCN response criteria, measured by ORR (CR/CRh)
Time frame: From date of first dose of AZD4512 up until end of study, up to 38 months
Module 2 (Dose Optimization): Frequency, duration and severity of treatment-emergent adverse events (TEAEs), treatment-related adverse events (TRAEs), and serious adverse events (SAEs)
Assessed by the CTCAE criteria version 5.0
Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
Module 2 (Dose Optimization): Frequency of dose interruptions, modifications, delays, and discontinuations due to AEs
Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
Module 2 (Dose Optimization): Number of participants with clinically significant changes in laboratory values, ECGs, performance status, and vital signs
Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
Module 1 (Dose Escalation): Plasma PK parameters of AZD4512
To characterize the PK of AZD4512 as monotherapy in participants with R/R B-ALL.
Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
Module 1 (Dose Escalation): Total antibody and total unconjugated payload
To characterize the PK of AZD4512 as monotherapy in participants with R/R B-ALL.
Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
Module 1 (Dose Escalation): Area Under Curve (AUC)
To characterize the PK of AZD4512 as monotherapy in participants with R/R B-ALL.
Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
Module 1 (Dose Escalation): Peak Plasma Concentration (Cmax)
To characterize the PK of AZD4512 as monotherapy in participants with R/R B-ALL.
Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
Module 1 (Dose Escalation): Time to max concentration (Tmax)
To characterize the PK of AZD4512 as monotherapy in participants with R/R B-ALL.
Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
Module 1 (Dose Escalation): Half life (T1/2)
To characterize the PK of AZD4512 as monotherapy in participants with R/R B-ALL.
Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
Module 1 (Dose Escalation): Clearance (CL)
To characterize the PK of AZD4512 as monotherapy in participants with R/R B-ALL.
Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
Module 1 (Dose Escalation): Volume of distribution (Vz)
To characterize the PK of AZD4512 as monotherapy in participants with R/R B-ALL.
Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
Module 1 (Dose Escalation): Number and percentage of participants who develop anti-drug antibodies (ADAs)
To determine the immunogenicity of AZD4512 as monotherapy in participants with R/R B-ALL.
Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
Module 1 (Dose Escalation): Objective Response Rate (ORR): proportion of participants with CR or CRh
To evaluate the preliminary efficacy of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-) and Ph(+)\] as defined by NCCN guidelines
Time frame: From date of first dose of AZD4512 up until end of study, up to 38 months
Module 1 (Dose Escalation): Composite Complete Remission (CRc) rate: proportion of participants with CR, CRh, or CRi
To evaluate the preliminary efficacy of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-) and Ph(+)\] as defined by NCCN guidelines
Time frame: From date of first dose of AZD4512 up until end of study, up to 38 months
Module 1 (Dose Escalation): Complete Remission (CR) rate
To evaluate the preliminary efficacy of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-) and Ph(+)\] as defined by NCCN guidelines
Time frame: From date of first dose of AZD4512 up until end of study, up to 38 months
Module 1 (Dose Escalation): Time to Response (TTR)
To evaluate the preliminary efficacy of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-) and Ph(+)\] as defined by NCCN guidelines
Time frame: From date of first dose of AZD4512 up until end of study, up to 38 months
Module 1 (Dose Escalation): Duration of Response (DoR)
\- To evaluate the preliminary efficacy of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-) and Ph(+)\] as defined by NCCN guidelines
Time frame: From date of first dose of AZD4512 up until end of study, up to 38 months
Module 1 (Dose Escalation): Event-Free Survival (EFS)
\- To evaluate the preliminary efficacy of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-) and Ph(+)\] as defined by NCCN guidelines
Time frame: From date of first dose of AZD4512 up until end of study, up to 38 months
Module 1 (Dose Escalation): Overall Survival (OS)
\- To evaluate the preliminary efficacy of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-) and Ph(+)\] as defined by NCCN guidelines
Time frame: From date of first dose of AZD4512 up until end of study, up to 38 months
Module 1 (Dose Escalation): Percentage of participants who receive subsequent allogeneic hematopoietic stem cell transplant (HSCT)
\- To evaluate the preliminary efficacy of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-) and Ph(+)\] as defined by NCCN guidelines
Time frame: From date of first dose of AZD4512 up until end of study, up to 38 months
Module 2 (Dose Optimization): Complete Remission (CR) rate
To evaluate the efficacy of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-)\] as defined by NCCN guidelines
Time frame: From date of first dose of AZD4512 up until end of study, up to 38 months
Module 2 (Dose Optimization):Composite Complete Remission (CRc) rate: proportion of participants with CR, CRh, or CRi
To evaluate the efficacy of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-)\] as defined by NCCN guidelines
Time frame: From date of first dose of AZD4512 up until end of study, up to 38 months
Module 2 (Dose Optimization):Time to Response (TTR)
To evaluate the efficacy of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-)\] as defined by NCCN guidelines
Time frame: From date of first dose of AZD4512 up until end of study, up to 38 months
Module 2 (Dose Optimization): Duration of Response (DoR)
To evaluate the efficacy of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-)\] as defined by NCCN guidelines
Time frame: From date of first dose of AZD4512 up until end of study, up to 38 months
Module 2 (Dose Optimization):Event-Free Survival (EFS)
To evaluate the efficacy of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-)\] as defined by NCCN guidelines
Time frame: From date of first dose of AZD4512 up until end of study, up to 38 months
Module 2 (Dose Optimization): Overall Survival (OS)
To evaluate the efficacy of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-)\] as defined by NCCN guidelines
Time frame: From date of first dose of AZD4512 up until end of study, up to 38 months
Module 2 (Dose Optimization): Percentage of participants who receive subsequent allogeneic hematopoietic stem cell transplant (HSCT)
To evaluate the efficacy of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-)\] as defined by NCCN guidelines
Time frame: From date of first dose of AZD4512 up until end of study, up to 38 months
Module 2 (Dose Optimization): MRD-negative CR rate, CR/CRh (ORR), CR/CRi/CRh (CRc) rate
To evaluate the impact of AZD4512 on MRD as assessed by NGS (central)
Time frame: From date of first dose of AZD4512 up until end of study, up to 38 months
Module 2 (Dose Optimization): Plasma PK parameters of AZD4512
To characterize the PK of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-)\]
Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
Module 2 (Dose Optimization): total antibody and total unconjugated payload
To characterize the PK of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-)\]
Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
Module 2 (Dose Optimization): Area Under Curve (AUC)
To characterize the PK of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-)\]
Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
Module 2 (Dose Optimzation): Peak Plasma Concentration (Cmax)
To characterize the PK of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-)\]
Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
Module 2 (Dose Optimization): Time to max concentration (Tmax)
To characterize the PK of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-)\]
Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
Module 2 (Dose Optimization): Half life (T1/2)
To characterize the PK of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-)\]
Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
Module 2 (Dose Optimization): Clearance (CL)
To characterize the PK of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-)\]
Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
Module 2 (Dose Optimization): Volume of distribution (Vz)
To characterize the PK of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-)\]
Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
Module 2 (Dose Optimization): Summary of of pre-existing and treatment induced ADAs for AZD4512 (positive or negative, titers)
To determine the immunogenicity of AZD4512 as monotherapy in participants with R/R B-ALL \[Ph(-)\]
Time frame: From date of first dose of AZD4512 up until 30 days post last dose of AZD4512 (on average 6 months, maximum 12 months)
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Oct 2028, 34 months after the start.
Of 50 phase 1/2 interventional studies under Burkitt Lymphoma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 114. This study's planned 34 months is below that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Apr 2028 → Oct 2028 and completion Jul 2028 → Jul 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.